Welcome!
I'm Ken Karapetyan, founder of Consulting Lab. Fractional product leadership for biotech and AI health-tech, and digital and AI strategy for established R&D organizations.
Where teams stall
The science works, but the story doesn't survive a meeting with a pharma buyer or an investor who has seen forty decks this quarter.
The roadmap is built from what the team can do rather than from what a customer will pay for, and nobody has said so out loud.
The AI programs produce impressive demos that nobody uses twice, and nobody can tell whether the problem is the technology or the data underneath it.
If one of those sounds like your last leadership meeting, we should talk.
Three seats, one market
I've built and commercialized scientific software and AI products from inside pharmaceutical R&D, from inside the companies that sell into it, and from inside the public research infrastructure both depend on.
That's the difference. When I tell you what a pharma buyer will actually pay for, I'm not guessing. I've been that buyer.
What the first month looks like
I start by finding the decision that's stuck. Not the technology, not the backlog. Which call your team can't make, who owns it, and what would have to be true for them to make it differently.
By the end of the first month you'll have a clear answer on what to build next, what to stop building, and how to say it to a buyer or a board.